Allogeneic Transplant in HIV Patients (BMT CTN 0903)

• ClinicalTrials.gov Identifier: NCT01410344
• Recruitment Status: Completed
• First Posted: August 5, 2011
• Results First Posted: May 24, 2018
• Last Update Posted: December 8, 2022
• Sponsor: Medical College of Wisconsin
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network; National Marrow Donor Program
• Information provided by (Responsible Party): Medical College of Wisconsin

Study Description

Brief Summary:

The rationale for this trial is to demonstrate the feasibility and safety of allogeneic HCT for patients with chemotherapy-sensitive hematological malignancies and coincident HIV-infection. In particular, the trial will focus on the 100-day non-relapse mortality as an indicator of the safety of transplant in this patient population. Correlative assays will focus upon the incidence of infectious complications in this patient population, the evolution of HIV infection and immunological reconstitution. Where feasible (and when this can be accomplished without compromise of either the donor quality or the timeliness of transplantation), an attempt will be made to identify donors who are homozygotes for the delta32 mutation for CCR5.

Condition or disease	Intervention/treatment	Phase
Leukemia; Lymphoma; HIV	Drug: Fludarabine and Busulfan; Drug: Fludarabine and Melphalan; Drug: Busulfan and Fludarabine; Drug: Cyclophosphamide and Total Body Irradiation	Phase 2

Detailed Description:

The study is designed to evaluate the feasibility and safety of reduced-intensity and fully-ablative allogeneic hematopoietic cell transplantation (HCT) for patients with hematological malignancies or myelodysplastic syndromes (MDS) who have HIV infection. The goal of the study is to assess the 100 day Non-relapse Mortality as well as immunological reconstitution in this patient population. Where feasible, an attempt will be made to identify human leukocyte antigen (HLA)-compatible hematopoietic stem cell donors who are homozygotes for the delta32 mutation of the chemokine receptor 5 (CCR5delta32). Patients will undergo a treatment plan review prior to registration on the trial. All patients will undergo allogeneic HCT from a matched sibling or unrelated donor.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 20 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)
• Actual Study Start Date: September 2011
• Actual Primary Completion Date: November 2016
• Actual Study Completion Date: June 2018

Arms and Interventions

Arm

Intervention/treatment

Allogeneic Transplant; One regimen from either reduced-intensity conditioning (RIC) (Fludarabine and Busulfan; or Fludarabine and Melphalan) or myeloablative conditioning (MAC) (Busulfan and Fludarabine; or Cyclophosphamide and Total Body Irradiation) will be administered prior to allogeneic hematopoietic cell transplantation (HCT).

Drug: Fludarabine and Busulfan; RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen: Days -6 to -2: Flu (30 mg/m^2/day, total dose of 150 mg/m^2); Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m^2 IV, respectively) Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage. Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW.; Other Name: Fludara and Busulfex; Drug: Fludarabine and Melphalan; RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m^2, Melphalan total dose: less than or equal to 150 mg/m^2. Recommended regimen: Days -5 to -2: Flu (30mg/m^2/day, total dose of 120 mg/m^2); Day -1: Mel (140mg/m^2) Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.; Other Name: Fludara and Alkeran; Drug: Busulfan and Fludarabine; MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen: Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively); Days -5 to -2: Flu (30 mg/m^2/day, total dose of 120 mg/m^2) Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage. Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW.; Other Name: Busulfex and Fludara; Drug: Cyclophosphamide and Total Body Irradiation; MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen: Days -7 to -4: TBI (total dose of 1200-1420 cGy); Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg) Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight.; Other Name: Cytoxan® and radiation

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants With Non-Relapse Mortality [ Time Frame: Day 100, 1 Year, and 2 Years Post-transplant ]
   The events for non-relapse mortality are death due to any cause other than relapse of the underlying malignancy.

Secondary Outcome Measures :

1. Percentage of Participants With Overall Survival [ Time Frame: Six months, 1 Year, and 2 Years Post-transplant ]
   Overall survival is defined as the time from transplant to death from any cause.
2. Percentage of Participants With Relapse/Progression [ Time Frame: 1 Year Post-transplant ]
   Relapse/Progression is defined as relapse or progression of the primary malignancy.
3. Primary Cause of Death [ Time Frame: Up to 2 Years Post-transplant ]
4. Disease Status [ Time Frame: Day 100 Post-transplant ]
   Patients will be assessed for disease status at Day 100 post-HCT, classified as complete remission, partial remission, stable disease, and relapse/progressive disease.
5. Percentage of Participants Recovering Hematologic Function [ Time Frame: Days 28 and 100 Post-transplant ]
   Recovery of hematologic function is described by the time to neutrophil and platelet recovery. Time to neutrophil recovery will be the first of three consecutive days of > 500 neutrophils/μL following the expected nadir. Time to platelet engraftment will be described by the date when platelet count is > 20,000/μL for the first of three consecutive labs with no platelet transfusions 7 days prior.
6. Chimerism [ Time Frame: Week 4, Day 100, and 6 months Post-transplant ]
   Donor T-cell and myeloid chimerism will be described separately by conditioning regimen intensity (myeloablative or reduced intensity) according to proportions with mixed chimerism (5-95% donor cells out of all), full chimerism (>95% donor cells), or graft rejection (<5% donor cells).
7. Percentage of Participants With Acute Graft-Versus-Host Disease (GVHD) [ Time Frame: Day 100 Post-transplant ]

   Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:

   Skin stage:

   0: No rash

   1. Rash <25% of body surface area
   2. Rash on 25-50% of body surface area
   3. Rash on > 50% of body surface area
   4. Generalized erythroderma with bullous formation

   Liver stage (based on bilirubin level)*:

   0: <2 mg/dL 1.2-3 mg/dL 2.3.01-6 mg/dL 3.6.01-15.0 mg/dL 4.>15 mg/dL

   GI stage*:

   0: No diarrhea or diarrhea <500 mL/day

   1. Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
   2. Diarrhea 1000-1499 mL/day
   3. Diarrhea >1500 mL/day
   4. Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.

   GVHD grade:

   0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4

8. Percentage of Participants With Chronic Graft-Versus-Host Disease (GVHD) [ Time Frame: 1 Year Post-transplant ]
   Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification.
9. Infection Severity [ Time Frame: 1 Year Post-transplant ]
   The maximum grade of infections reported by participants are described, as defined in the BMT CTN Technical MOP.

Eligibility Criteria

• Ages Eligible for Study: 15 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. HIV-1 infection, as documented by a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time prior to study entry. HIV antigen, plasma HIV-1 RNA, or a secondary antibody test by a method other than rapid HIV and E/CIA is acceptable as an alternative test. Alternatively, if a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test is not available, two HIV-1 RNA values ≥ 2000 copies/mL at least 24 hours apart performed by any laboratory that has CLIA certification, or its equivalent, may be used to document infection.
2. Patients must be willing to comply with effective Antiretroviral Therapy.
3. Patients must be ≥ 15 years of age.

4. Hematological malignancy associated with a poor prognosis with medical therapy alone. Diagnoses to be included:

   1. Patients with the diagnosis of Acute Myeloid or Lymphocytic Leukemia (AML or ALL) in first or second complete remission.
   2. Patients with advanced myelodysplastic syndromes (MDS), including those with International Prognostic Scoring System (IPSS) Int-2 and high-risk disease with less than 10% marrow blasts and no circulating myeloblasts after most recent therapy. Patients with acute leukemia that develops from a pre-existing MDS must meet the inclusion criteria for patients with AML detailed above.
   3. Hodgkin Lymphoma beyond first remission achieving at least a partial response to most recent therapy with no evidence of progression prior to transplant.
   4. Non-Hodgkin Lymphoma beyond first remission achieving at least a partial response to most recent therapy with no evidence of progression prior to transplant.

5. Donor/Recipient HLA Matching:

   1. Related donor: must be an 8/8 match at HLA-A, -B, -C, (serologic typing or higher resolution) and -DRB1 (at high resolution using DNA based typing). A 7/8 related donor match is permitted only if an 8/8 unrelated donor cannot be identified.
   2. Unrelated donor: must be a 7/8 or 8/8 match at HLA-A, -B, -C, and -DRB1 (at high resolution using DNA based typing).

6. Patients with adequate organ function as measured by:

   1. Cardiac: Left ventricular ejection fraction at rest ≥ 40% demonstrated by Multi Gated Acquisition Scan (MUGA) or echocardiogram. Patients with known heart disease must have a functional status no worse than American Heart Association Class I defined as patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.
   2. Hepatic:

   i. Total Bilirubin < 2.0 mg/dL (except for isolated hyperbilirubinemia attributed to Gilbert syndrome or antiretroviral therapy as specified in Appendix E) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5x the upper limit of normal.

   ii. Concomitant Hepatitis: Patients with chronic hepatitis B or C may be enrolled on the trial providing the above bilirubin and transaminase criteria are met. In addition, there must be no clinical or pathologic evidence of irreversible chronic liver disease, and there must be no active viral replication as evidenced by an undetectable hepatitis viral load by a PCR-based assay.

   c) Renal: Creatinine clearance (calculated creatinine clearance is permitted) > 40 mL/min.

   d) Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), or forced vital capacity (FVC) ≥ 45% of predicted (corrected for hemoglobin).

7. Signed Informed Consent

Exclusion Criteria:

1. Karnofsky/Lansky performance score < 70%.
2. Active central nervous system (CNS) malignancy; however, patients with a history of positive Cerebrospinal fluid (CSF) cytology that has become negative with intrathecal chemotherapy are eligible.
3. Uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression or no clinical improvement).
4. Active Cytomegalovirus (CMV) retinitis or other CMV-related organ dysfunction.
5. AIDS related syndromes or symptoms that pose a perceived excessive risk for transplantation-related morbidity as determined by the principal investigator.
6. Untreatable HIV infection due to multidrug antiretroviral resistance. Patients with a detectable viral load > 750 copies/ml should be evaluated with an HIV drug resistance test (HIV-1 genotype). The results should be included as part of the Antiretroviral Review (described in Appendix D). This Review Committee will make the final determination as to whether HIV viremia could potentially be suppressed with alternate antiretroviral therapy. .
7. Pregnant (positive β-HCG) or breastfeeding.
8. Fertile men or women unwilling to use contraceptive techniques from the time of initiation of mobilization until six-months post-transplant.
9. Prior allogeneic HCT.
10. Patients with psychosocial conditions that would prevent study compliance and follow-up, as determined by the principal investigator.
11. T-cell depletion (including ATG or alemtuzumab) is not allowed.
12. Use of cord blood as the source of hematopoietic cells is not allowed.

Contacts and Locations

Locations

United States, Arizona

Mayo Clinic - Phoenix

Phoenix, Arizona, United States, 85054

United States, California

City of Hope National Medical Center

Duarte, California, United States, 91010

University of CA, SF

San Francisco, California, United States, 94143-0324

United States, Florida

H. Lee Moffitt Cancer Center

Tampa, Florida, United States, 33624

United States, Georgia

Blood & Marrow Transplant Program at Northside Hospital

Atlanta, Georgia, United States, 30342

United States, Maryland

Johns Hopkins

Baltimore, Maryland, United States, 21231

United States, Minnesota

Mayo Clinic - Rochester

Rochester, Minnesota, United States, 55905

United States, Pennsylvania

University of Pennsylvania Cancer Center

Philadelphia, Pennsylvania, United States, 19104

United States, Texas

University of Texas/MD Anderson CRC

Houston, Texas, United States, 77030

Texas Transplant Institute

San Antonio, Texas, United States, 78229

United States, Wisconsin

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53211

Sponsors and Collaborators

Medical College of Wisconsin

National Heart, Lung, and Blood Institute (NHLBI)

National Cancer Institute (NCI)

Blood and Marrow Transplant Clinical Trials Network

National Marrow Donor Program

Investigators

• Study Director: Mary Horowitz, MD; Center for International Blood and Marrow Transplant Research

  Study Documents (Full-Text)

Documents provided by Medical College of Wisconsin:

Study Protocol and Informed Consent Form  [PDF] February 18, 2014

Statistical Analysis Plan  [PDF] March 23, 2018

More Information

Additional Information:

Blood and Marrow Transplant Clinical Trials Network 

National Marrow Donor Program 

Publications of Results:

Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC. Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. Biol Blood Marrow Transplant. 2019 Nov;25(11):2160-2166. doi: 10.1016/j.bbmt.2019.06.033. Epub 2019 Jul 4.

• Responsible Party: Medical College of Wisconsin
• ClinicalTrials.gov Identifier: NCT01410344
• Other Study ID Numbers: BMTCTN0903; U01HL069294 ( U.S. NIH Grant/Contract ); BMT CTN 0903 ( Other Identifier: Blood and Marrow Transplant Clinical Trials Network ); 5U24CA076518 ( U.S. NIH Grant/Contract )
• First Posted: August 5, 2011
• Results First Posted: May 24, 2018
• Last Update Posted: December 8, 2022
• Last Verified: December 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).
• Supporting Materials: Study Protocol; Informed Consent Form (ICF)
• Time Frame: Within 6 months of official study closure at participating sites.
• Access Criteria: Available to the public
• URL: https://biolincc.nhlbi.nih.gov/home/

Keywords provided by Medical College of Wisconsin:

HIV; ALL; AML; MDS; Non-Hodgkin Lymphoma

Additional relevant MeSH terms:

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Vidarabine; Cyclophosphamide; Melphalan; Busulfan; Fludarabine; Fludarabine phosphate; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists; Antimetabolites, Antineoplastic; Antimetabolites; Antiviral Agents; Anti-Infective Agents